Prognostic value of 18F-FDG PET/CT volumetric parameters in recurrent epithelial ovarian cancer

Revista Espanola de Medicina Nuclear e Imagen Molecular

Volumn 35, Issue 2, 2016, Pages 88-95

  Mayoral, M ^a   Fernandez Martinez, A ^a   Vidal, L ^a   Fuster, D ^a,b   Aya, F ^a   Pavia, J ^a,b,c   Pons, F ^a,b   Lomena F ^a,b   Paredes, P ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

18F FDG PET CT; Metabolic tumour volume; Progression free survival; Recurrent epithelial ovarian cancer; Total lesion glycolysis

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; OVARY CANCER; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME; DIAGNOSTIC IMAGING; FEMALE; METABOLISM; MORTALITY; MULTIMODAL IMAGING; OVARY TUMOR; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROGNOSIS; TUMOR RECURRENCE; X-RAY COMPUTED TOMOGRAPHY;

FEMALE; HUMANS; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 84958149811     PISSN: 2253654X     EISSN: 22538070     Source Type: Journal    
DOI: 10.1016/j.remn.2015.08.005     Document Type: Article

References (30)

1. Jemal A., Bray F., Ferlay J. Global Cancer. Statistics 2011, 61:69-90.
2. Heintz A.P.M., Odicino F., Maisonneuve P., Quinn M.A., Benedet J.L., Creasman W.T., et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006, 95:S161-S192.
3. Aabo K., Adams M., Adnitt P., Alberts D.S., Athanazziou A., Barley V., et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Br J Cancer 1998, 78:1479-1487.
4. StatBite Ovarian cancer: risk of recurrence by stage of diagnosis. J Natl Cancer Inst 2009, 101:1234.
5. Limei Z., Yong C., Yan X., Shuai T., Jiangyan X., Zhiqing L. Accuracy of positron emission tomography/computed tomography in the diagnosis and restaging for recurrent ovarian cancer: a meta-analysis. Int J Gastrointest Cancer 2013, 23:598-607.
6. Sanli Y., Turkmen C., Bakir B., Iyibozkurt C., Ozel S., Has D., et al. Diagnostic value of PET/CT is similar to that of conventional MRI and even better for detecting small peritoneal implants in patients with recurrent ovarian cancer. Nucl Med Commun 2012, 33:509-515.
7. Fulham M.J., Carter J., Baldey a, Hicks R.J., Ramshaw J.E., Gibson M. The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multi-centre study as part of the Australian PET Data Collection Project. Gynecol Oncol 2009, 112:462-468.
8. Tanizaki Y., Kobayashi A., Shiro M., Ota N., Takano R., Mabuchi Y., et al. Diagnostic value of preoperative SUVmax on FDG-PET/CT for the detection of ovarian cancer. Int J Gastrointest Cancer 2014, 24:454-460.
9. 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun 2007, 28:589-595.
10. Avril N., Sassen S., Schmalfeldt B., Naehrig J., Rutke S., Weber W., et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 2005, 23:7445-7453.
11. Sala E., Kataoka M., Pandit-Taskar N., Ishill N. Recurrent ovarian cancer: use of contrast-enhanced CT and PET/CT to accurately localize tumor recurrence and to predict patients' survival 1. Radiology 2010, 257:125-134.
12. Nakamura K., Hongo A. The pretreatment of maximum standardized uptake values (SUVmax) of the primary tumor is predictor for poor prognosis for patients with epithelial ovarian cancer. Acta Med Okayama 2012, 66:53-60.
13. 18F-FDG PET/CT in squamous cell carcinoma of the oral cavity. Eur J Nucl Med Mol Imaging 2014, 41:452-461.
14. 18F-FDG PET-CT parameters for predicting survival in recurrent carcinoma of the cervix. Nucl Med Commun 2013, 34:741-748.
15. 18F-FDG PET/CT in the prognosis of epithelial ovarian cancer. Eur J Nucl Med Mol Imaging 2014, 41:1898-1906.
16. 18F-FDG PET/CT in post-surgical patients with epithelial ovarian cancer. Clin Nucl Med 2013, 38:715-720.
17. Chung H.H., Kwon H.W., Kang K.W., Park N.-H., Song Y.-S., Chung J.-K., et al. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer. Ann Surg Oncol 2012, 19:1966-1972.
18. Vargas H.A., Burger I.A., Goldman D.A., Micco M., Sosa R.E., Weber W., et al. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery. Eur Radiol 2015, 25:3348-3353.
19. Kim C.-Y., Jeong S.Y., Chong G.O., Son S.H., Jung J.-H., Kim D.-H., et al. Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer. Gynecol Oncol 2015, 136:498-504.
20. 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary. Gynecol Oncol 2014, 133:100-104.
21. Boellaard R., Delgado-Bolton R., Oyen W.J.G., Giammarile F., Tatsch K., Eschner W., et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2014, 42:328-354.
22. Network C.G.A.R. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
23. 18F-fluoro-2-deoxy-glucose positron emission tomography/computed tomography and glucose transporter-1 expression correlates with survival in invasive ductal carcinoma of the pancreas. Pancreas 2014, 43:1060-1065.
24. Rockall A.G., Avril N., Lam R., Iannone R., Mozley P.D., Parkinson C., et al. Repeatability of quantitative FDG-PET/CT and contrast-enhanced CT in recurrent ovarian carcinoma: test-retest measurements for tumor fdg uptake, diameter, and volume. Clin Cancer Res 2014, 20:2751-2760.
25. Uto F., Shiba E., Onoue S., Yoshimura H., Takada M., Tsuji Y., et al. Phantom study on radiotherapy planning using PET/CT. J Radiat Res 2010, 51:157-164.
26. Paidpally V., Mercier G., Shah B.a., Senthamizhchelvan S., Subramaniam R.M. Interreader agreement and variability of FDG PET volumetric parameters in human solid tumors. Am J Roentgenol 2014, 202:406-412.
27. 18F-deoxyglucose positron emission tomography in suspected recurrence of epithelial ovarian cancer. Strahlenther Onkol 2004, 180:497-501.
28. 18F-FDG PET/CT in detection of recurrent epithelial ovarian carcinomas. Clin Nucl Med 2012, 37:184-188.
29. Lorusso D., Mancini M., Di Rocco R., Fontanelli R., Raspagliesi F. The role of secondary surgery in recurrent ovarian cancer. Int J Surg Oncol 2012, 2012:613980.
30. Ferrero A., Ditto A., Giorda G., Gadducci A., Greggi S., Daniele A., et al. Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study. Eur J Surg Oncol 2014, 40:891-898.